Support available for people impacted by the Bondi Junction tragedy: Read more


Immunisation Weekly Update:

20190319 Immunisation Needle Icons 31

Immunisation education

View past webinar recordings on our Immunisation | Education webpage.


30 April 2024 6:00pm – 9:00pm
Free event: Respiratory Infections and the Role of Vaccines

An evening of networking, drinks, canapes, and expert talks on respiratory diseases and vaccines. Topics include update on viral epidemiology, management of acute respiratory infections in children, prevention of respiratory syncytial virus in children, and more.

1-2 May 2024 2 day event – $600
Benchmarque Group’s 2024 Immunisation Professional Development Conference

The purpose of the event is to deliver a blend of hands-on skills-based workshops, and updates from experts in the field.   Content will include COVID and the changing focus in Primary Healthcare, Managing RSV in Primary Healthcare Settings, NIP and priority populations, Vaccine Hesitancy, Culturally Safe Practice in Immunisation, Vaccine Strategies and Promotions, Travel vaccines and Complex Catch-Ups.    

RSV Vulnerable Babies Program in NSW

The RSV Vulnerable Babies Program funds nirsevimab, a long-acting monoclonal antibody against RSV disease, for eligible infants in NSW. ATAGI statement. International supply is limited and Beyfortus® (nirsevimab) is not currently available beyond state-based programs. See ATAGI statement.

Update: AIH Influenza – specified medical conditions table

The Australian Immunisation Handbook has recently included an easy-to-read table detailing the specified medical conditions associated with increased risk of influenza disease and severe outcomes and access to free influenza vaccination under the National Immunisation Program for people with these conditions.

2024 seasonal influenza vaccine safety data

AusVaxSafety commenced active surveillance of 2024 seasonal influenza vaccines on 18 March 2024.

In the first reporting period, 18–31 March 2024, more than 4,000 vaccine safety surveys were completed by individuals (or their parents/carers) who received an influenza vaccine and participated in the AusVaxSafety surveillance program. 

Early data reveals that in the period under review, more than four-fifths (82.6%) of influenza vaccine recipients experienced no adverse events in the three days following vaccination.

AusVaxSafety began monitoring the safety of influenza vaccines administered to Australians of all ages in 2017. Since then, more than 1 million people (or their parents/carers) have provided details about adverse events experienced after influenza vaccination.

Influenza vaccine safety data will be updated on the AusVaxSafety website weekly throughout the 2024 flu season.

Q fever vaccines to be added to AIR

From 15 April 2024, vaccination providers will be able to report information about Q fever vaccination and natural immunity status to the Australian Immunisation Register (AIR).

Providers will be able to update an individual’s AIR record based on information in their Q Fever eStatement and other supporting documentation, taking into account Australian Immunisation Handbook recommendations.

This initiative will support the closure of the Australian Q Fever Register. However, individuals can access their information on the Q Fever Register – including their Q Fever eStatement – until 30 June 2025. See media release.

NCIRS webinar recordings: Respiratory disease in 2024

The NCIRS webinar series on preventing respiratory disease in 2024 recently concluded with an informative session on influenza and COVID-19 vaccination.

Video recordings of that event – as well as the two earlier webinars on respiratory syncytial virus (RSV) – are now available on the Immunisation | Education webpage.